LIFEPHARMS, INC.

Basic Information

143 Shaw Street
New London, CT, 06320-

Company Profile

n/a

Additional Details

Field Value
DUNS: 172904067
Hubzone Owned: N
Socially and Economically Disadvantaged: Y
Woman Owned: N
Number of Employees: n/a


  1. Antifungal therapy against drug resistant fungal pathogens.

    Amount: $774,112.00

    DESCRIPTION provided by applicant Despite medical advances fungal infections still exact a heavy burden on the HIV AIDs population AIDs related fungal infections account for of all AIDs relate ...

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Hsp90 inhibitors to combat antifungal drug resistance.

    Amount: $299,998.00

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV-infected patients. Many of the emerging fungal pathogens that are resistant to ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Novel Antibacterial Scaffold from Natural Products

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Despite the rise of bacterial resistance to antibiotics, the development of new antibiotics is on the decline. Methicillin-resistant Staphococcal aureus infections ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Novel antifungals for Immunocompromised/HIV patients.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV- infected patients. At present, there are only three classes of antifungal age ...

    SBIR Phase I 2011 Department of Health and Human Services
  5. Discovery of novel agents against M. tuberculosis.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Despite the fact that tuberculosis is a major public global health problem, there have been no drugs developed for it since the 1960s. In 2006 tuberculosis caused ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Nucleoside hydrolase Inhibitors from natural products for Leishmania

    Amount: $211,698.00

    DESCRIPTION (provided by applicant): Our goal is to identify novel drugs for the treatment and chemoprophylaxis of Leishmania by blocking nucleoside hydrolase (NH) activity of this parasite. Leishmani ...

    SBIR Phase I 2010 Department of Health and Human Services
  7. Discovery of novel antibacterials from a mushroom natural product library

    Amount: $378,012.00

    DESCRIPTION (provided by applicant): The dramatic increase in the prevalence of antibiotic resistance among important hospital- and community-acquired bacterial pathogens poses a serious threat to our ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Discovery of cell cycle inhibitors from natural products

    Amount: $904,482.00

    DESCRIPTION (provided by applicant): The need for new and effective chemotherapeutic agents that selectively target cancer cells and thus, would have a much higher therapeutic index is urgent. Most c ...

    SBIR Phase II 2005 Department of Health and Human Services
  9. POTENTIAL ANTICANCER AGENTS FROM BASIDIOMYCETES

    Amount: $100,000.00

    LifePharms, Inc. has established a collection of >12,000 unique species of basidiomycetes/ascomycetes, and the Natural Products Laboratory of Research Triangle Institute has a long and successful hist ...

    SBIR Phase I 2001 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government